Literature DB >> 21897753

The effect of the expenditure increase in the morbidity and the mortality of patients with end stage renal disease: the USA case.

A Letsios1.   

Abstract

The worldwide incidence of kidney failure is on the rise and treatment is costly. Kidney failure patients require either a kidney transplant or dialysis to maintain life. This review focuses on the economics of alternative dialysis modalities such as haemodialysis (HD) and peritoneal dialysis (PD). Important economic factors influencing dialysis modality selection include financing, reimbursement and resource availability. Modality selection is also influenced by employment status, with an association between being employed and PD as the modality choice.In the United States, there were 101,688 incident HD patients and 6,506 incident PD patients in 2007. Due to the fact that the worldwide incidence of kidney failure continues to rise placing USA in the second position right after Taiwan, the accumulated experience from USA could be used as a characteristic prototype for the analysis of the economics related with modality choices and their influence in the quality of life and life expectancy of end stage renal disease (ESRD) patients.In the present work we discuss the effect of the expenditure increase in the morbidity and the mortality of patients with end stage renal disease. Data coming from the USA case concerning the economic factors which play a vital role in the sequence of events that leads to the choice between different modalities such as HD and PD, will be used as a distinctive example in our study. The relationship between the modality used and employment status is investigated. The cost effectiveness of alternative modalities is reviewed. Examples of statistical models and simulation approaches, studying the increase of the life expectancy in terms of the quality adjusted life years (QALYs) and the incremental cost paid are also presented. Corresponding results originated from different regions of the world are also briefly shown.

Entities:  

Keywords:  ESRD; RRT; cost; economic factors; haemodialysis; peritoneal dialysis

Year:  2011        PMID: 21897753      PMCID: PMC3139673     

Source DB:  PubMed          Journal:  Hippokratia        ISSN: 1108-4189            Impact factor:   0.471


  35 in total

1.  The cost barrier to peritoneal dialysis in the developing world--an Asian perspective.

Authors:  P K Li; K M Chow
Journal:  Perit Dial Int       Date:  2001       Impact factor: 1.756

2.  Health insurance reform: standard unique employer indentifier. Final rule.

Authors: 
Journal:  Fed Regist       Date:  2002-05-31

3.  The state of peritoneal dialysis in France.

Authors:  Pierre-Yves Durand; Christian Verger
Journal:  Perit Dial Int       Date:  2006 Nov-Dec       Impact factor: 1.756

4.  Predicting a patient's choice of dialysis modality: experience in a United Kingdom renal department.

Authors:  J Little; A Irwin; T Marshall; H Rayner; S Smith
Journal:  Am J Kidney Dis       Date:  2001-05       Impact factor: 8.860

Review 5.  ESRD modality selection into the 21st century: the importance of non medical factors.

Authors:  A R Nissenson; S S Prichard; I K Cheng; R Gokal; M Kubota; R Maiorca; M C Riella; J Rottembourg; J H Stewart
Journal:  ASAIO J       Date:  1997 May-Jun       Impact factor: 2.872

6.  Analysis of patient flow into dialysis: role of education in choice of dialysis modality.

Authors:  Belén Marrón; Juan Carlos Martínez Ocaña; Mercedes Salgueira; Guillermina Barril; José M Lamas; Marisa Martín; Tomás Sierra; Ana Rodríguez-Carmona; Amparo Soldevilla; Francisco Martínez
Journal:  Perit Dial Int       Date:  2005-02       Impact factor: 1.756

7.  Developing a health-related quality-of-life measure for end-stage renal disease: The CHOICE Health Experience Questionnaire.

Authors:  A W Wu; N E Fink; K A Cagney; E B Bass; H R Rubin; K B Meyer; J H Sadler; N R Powe
Journal:  Am J Kidney Dis       Date:  2001-01       Impact factor: 8.860

8.  Changes in employment status in end-stage renal disease patients during their first year of dialysis.

Authors:  J G van Manen; J C Korevaar; F W Dekker; M C Reuselaars; E W Boeschoten; R T Krediet
Journal:  Perit Dial Int       Date:  2001 Nov-Dec       Impact factor: 1.756

9.  Quality of life in chronic dialysis patients: a critical comparison of continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis.

Authors:  D L Wolcott; A R Nissenson
Journal:  Am J Kidney Dis       Date:  1988-05       Impact factor: 8.860

10.  Quality of life in patients treated with hemodialysis or peritoneal dialysis: what are the important determinants?

Authors:  B Manns; J A Johnson; K Taub; G Mortis; W A Ghali; C Donaldson
Journal:  Clin Nephrol       Date:  2003-11       Impact factor: 0.975

View more
  5 in total

1.  Candida albicans-Staphylococcus aureus polymicrobial peritonitis modulates host innate immunity.

Authors:  Brian M Peters; Mairi C Noverr
Journal:  Infect Immun       Date:  2013-04-01       Impact factor: 3.441

2.  Cost of Hemodialysis Treatment and Associated Factors Among End-Stage Renal Disease Patients at the Tertiary Hospitals of Addis Ababa City and Amhara Region, Ethiopia.

Authors:  Daniel Asrat Kassa; Solomon Mekonnen; Adane Kebede; Tsegaye Gebremedhin Haile
Journal:  Clinicoecon Outcomes Res       Date:  2020-07-27

3.  Hemodialysis versus Peritoneal Dialysis: A Comparison of Survival Outcomes in South-East Asian Patients with End-Stage Renal Disease.

Authors:  Fan Yang; Lay-Wai Khin; Titus Lau; Horng-Ruey Chua; A Vathsala; Evan Lee; Nan Luo
Journal:  PLoS One       Date:  2015-10-07       Impact factor: 3.240

Review 4.  The cost of dialysis in low and middle-income countries: a systematic review.

Authors:  Lawrencia Mushi; Paul Marschall; Steffen Fleßa
Journal:  BMC Health Serv Res       Date:  2015-11-12       Impact factor: 2.655

5.  The impact of a remote monitoring system of healthcare resource consumption in patients on automated peritoneal dialysis (APD): A simulation study
.

Authors:  Kiyotaka Uchiyama; Naoki Washida; Nobuyuki Yube; Takahiro Kasai; Keisuke Shinozuka; Kohkichi Morimoto; Akihito Hishikawa; Hiroyuki Inoue; Hidenori Urai; Aika Hagiwara; Kentaro Fujii; Shu Wakino; Souzana Deenitchina; Hiroshi Itoh
Journal:  Clin Nephrol       Date:  2018-11       Impact factor: 0.975

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.